Twenty-six patients with HNSCC from the Asia-Pacific region received pembrolizumab.
HNSCC tops 600 000 cases annually, with more than half of all cases originating in the Asia-Pacific region. [1] [2] [3] In addition to the traditional HNSCC risk factors (ie, tobacco and alcohol use and human papillomavirus infection), 4, 5 other cultural influences, such as the chewing of betel nut, the consumption of products high in nitroso compounds, and exposure to Epstein-Barr virus, contribute to an increase in the occurrence of HNSCC in this region. [6] [7] [8] In Asia, a multimodal approach that combines platinum-based chemotherapy, radiotherapy, and another agent (preferably cetuximab), is recommended for the treatment of patients with recurrent/ metastatic HNSCC. 9 However, the concomitant use of cisplatin and cetuximab in advanced HNSCC is associated with substantial toxicity, 10 and therefore its use is limited in vulnerable populations, such as the elderly. 9 Although there are no standard alternatives, other commonly used second-line treatments (eg, methotrexate or taxanes)
are often plagued by low response rates (ranging from 3% to 13%). 5, 11 Thus, there is an unmet need in recurrent/metastatic HNSCC for treatment options that are both well tolerated and effective.
The PD-1 pathway is an important immune checkpoint that has been established as an effective target in HNSCC. [12] [13] [14] [15] Pembrolizumab, an anti-PD-1 antibody, has shown robust antitumor activity and a manageable safety profile in multiple tumor types, and is currently approved for one or more advanced malignancies, including in the USA for patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. 16 This approval was based on efficacy and safety outcomes from the phase Ib multicohort KEYNOTE-012 trial (ClinicalTrials.gov, NCT01848834). 16 KEYNOTE-012 included two HNSCC cohorts. The initial cohort (n = 60) enrolled only patients with PD-L1-positive tumors, and pembrolizumab 10 mg/kg was given every 2 weeks.
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The expansion cohort (n = 132) enrolled patients regardless of PD-L1 status, and pembrolizumab 200 mg was given every 3 weeks. 13 The confirmed ORR in both cohorts was 18%, and responses were durable. 12, 13 After a median follow-up of 14 months and 9 months in the initial and expansion cohorts, respectively, the median DOR was 53 weeks in the initial cohort and was not reached in the expansion cohort. 12, 13 Additionally, pembrolizumab was well tolerated in both cohorts, with treatment-related AEs of grade 3-4 severity occurring in 17% and 9% of patients, respectively.
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The HNSCC expansion cohort of KEYNOTE-012 included patients from the Asia-Pacific region. Here, we report the outcomes of this subgroup of patients.
| MATERIALS AND METHODS

| Patients
KEYNOTE-012 was a phase Ib, multicenter, non-randomized, multicohort trial designed to investigate the safety and efficacy of pembrolizumab in patients with advanced solid tumors. 12, 13, 17, 18 The study protocol and all amendments were approved by relevant regulatory and independent ethics committees. 
| Statistical analysis
Efficacy and safety analyses were undertaken in all patients who received one dose or more of pembrolizumab (all-patients-as-treated population). The subgroup analysis presented herein was restricted to patients receiving treatment at a site located in the Asia-Pacific region.
Exact methods for binomial parameters were used to determine ORR and 95% CIs per RECIST version 1.1. Patients with missing data were considered non-responders. Kaplan-Meier statistics were used to estimate PFS, OS, and DOR. Patients with missing survival data were censored at their last assessment. Non-responders were excluded from DOR analyses. The data cut-off date for these analyses was April 26, 2016.
3 | RESULTS
| Patients
In total, 26 patients with HNSCC were enrolled at one of five centers located in the Asia-Pacific region (National Cancer Center Hospital East, Kashiwa, Japan; Aichi Cancer Center Hospital, Nagoya, Japan;
Seoul National University Hospital, Seoul, Korea; Severance Hospital, Seoul, Korea; and National Taiwan University Hospital, Taipei, Taiwan).
The median age was 62 years (range, 44-73 years), 85% of patients were male, and 65% had ECOG PS 1 (Table 1) . With regard to traditional HNSCC risk factors, the majority of patients had a history of smoking (73%), whereas only two (8%) patients had human papillomavirus-associated disease. Patients were heavily pretreated; 61% had received two or more prior therapies for recurrent/metastatic disease and 92% had received prior platinum treatment (Table 1) an AE (n = 2); three patients were continuing on treatment.
Median pembrolizumab exposure at the data cut-off was 95 days (range, 1-617 days). Median follow-up at that time was 12 months (range, 2-21 months).
| Safety
Sixteen (62%) patients experienced treatment-related AEs of any grade, the most common of which were fatigue (n = 5), decreased appetite (n = 5), hypothyroidism (n = 4), and rash (n = 4) ( Table 2 ).
Two (8%) patients experienced ≥1 grade 3 treatment-related AEs:
one patient had an infection and another experienced decreased appetite and stomatitis (Table 2) . Two patients experienced serious treatment-related AEs, one of which led to the only discontinuation due to a treatment-related AE (grade 2 interstitial lung disease).
There were no treatment-related deaths. Immune-mediated AEs, which are reported regardless of attribution to treatment by the investigator, occurred in 5 (19%) patients: grade 2 hypothyroidism (n = 4), grade 3 drug-induced liver injury (n = 1), grade 2 interstitial lung disease (n = 1), and grade 2 pneumonitis (n = 1).
| Efficacy
At the data cut-off, five patients had achieved a confirmed PR, for an ORR of 19% (95% CI, 7%-39%); no patients achieved a CR ( patients who progressed after platinum-based therapy (n = 24), a confirmed ORR of 17% (95% CI, 5%-37%) was observed (Table 3) .
When the analysis was restricted to the 22 patients whose tumors expressed PD-L1 (CPS ≥1), the ORR was 23% (95% CI, 8%-45%).
Overall, a reduction in target lesion size was observed in 50% of patients, and most reductions were maintained over several imaging assessments ( Figure 1A ,B).
The median time to response was 1.9 months (range, 1.6-3.5 months) ( Figure 1C ). At the data cut-off, the median DOR was not reached (range, 6 to 17+ months), four out of five responses had lasted ≥6 months (Kaplan-Meier estimate), and 80% of responses were ongoing.
The median PFS was 2.1 months (95% CI, 1.9-5.4). The PFS rates at 6 and 12 months were 20% and 16%, respectively. Median OS was 11.6 months (95% CI, 4.7-17.7). The 6-month OS rate was 59%, and the 12-month OS rate was 46% ( Figure 1D ). options. However, the median OS with pembrolizumab in the present study (11.6 months) was similar to that reported in patients from China and Korea who were treated with the recommended first-line regimen of cisplatin/5-fluorouracil plus cetuximab (13 months). 24 Despite the heavily pretreated population in our study, the toxicity of pembrolizumab was notably better than the platinum and cetuximab regimen (grade 3-4 treatment-related AEs, 8% vs 44%). 24 A head-to-head comparison of pembrolizumab vs this standard first-line treatment regimen is underway in the phase III KEYNOTE-048 trial (ClinicalTrials.gov, NCT02358031).
| DISCUSSION
The results presented here add to a growing body of evidence supporting the use of pembrolizumab in patients with HNSCC. 12, 13, 15 This subgroup analysis is limited by the small number of patients 
